Penoxal Study

(Gynaecology and Obstetrics Outpatients of MUDr. Zdeněk Vocásek, Jihoslovanská 465, Vrchlabí) 

Total number of 52 patients (precancerosis of cervix) – 30 of those presenting with ASC-US (Atypical Squamous Cells of Undetermined Significance) and 22 patients with LSIL (Low-grade Squamous Intraepithelial Lesion), they had used Penoxal for 4 months in a dose of 100 mg 1–0–1.   

Follow-up cytology results:
 

1st ASC-US group (Atypical Squamous Cells of Undetermined Significance)

30 patients in total – follow-up cytology in 4 months

- Negative: 19

- LSIL: 2

- ASC-US: 5

- HSIL followed by cervical conisation: 2

- 2 patients failed to attend the follow-up sampling

 

2nd LSIL group – (Low-grade Squamous Intraepithelial Lesion, precancerosis of cervix)

22 patients in total – follow-up cytology in 4 months

- Negative: 8

- LSIL: 8

- ASC-US: 2

- HSIL followed by cervical conisation: 2

- 2 patients failed to attend the follow-up sampling

 

Patient sample: 

They were female patients presenting with cellular changes on cervical cytology that fall under dysplastic cellular changes and require continuing health care. There were two types of changes – ASC-US and LSIL. 

 

Study results: 

We investigated whether Penoxal could promote the function of the immune system and lead to a regression found on cytology. 

 

Effects of Penoxal on changes to ASC-US:

2/3 of the sample showed negative results after the use of preparation, the half of the remaining third showed same results, less than 7% had other dysplastic changes requiring continuing health care, and the changes deteriorated in 7% of patients who needed a surgical intervention. Two patients had failed to attend the follow-up smear.

 

Effects of Penoxal on changes to LSIL:

In 1/3 of patients (36.4%) the changes had disappeared completely after the use of Penoxal, one third of cases (36.4%) showed no changes, 9% of patients demonstrated a different type of mild dysplasia requiring continuing health care, and changes had become worse in 9% of patients who showed precancerosis and required a surgical intervention.  In two cases the patients failed to attend the follow-up smear. 

 

Study conclusions after 4 months of Penoxal use

The overall evaluation suggests that taking Penoxal for four months is more beneficial for female patients presenting with ASC-US cellular changes, because up to 2/3 of the cases demonstrated a complete recovery when compared to female patients presenting with LSIL dysplastic changes, where only 1/3 of patients had negative findings. Both groups demonstrated deterioration to the same extent. Overall, we may propose that over a half of follow-up smear tests (51.9%) were negative in those who were taking Penoxal for 4 months due to dysplastic changes found on cytology. 

 

The study was conducted by MUDr. Eva Zahradníková who represents the clinic of MUDr. Zdeněk Vocásek (Senior Consultant).

 

In Vrchlabí, 13/8/2018